Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission

Tropical Medicine Research Institute

Status and phase: Completed; Phase 3

Conditions: Asymptomatic Parataemia; Plasmodium Falciparum; Sub Patent Parasitaemia

Treatments: Drug: Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS); Drug: placebo tablet similar to active drug in shape and size

Study type: Interventional

Funder types: Other

Identifiers

NCT00646126

SUD 6/025

Details and patient eligibility

About

The malaria parasite Plasmodium falciparum remains at sub-patent level throughout the dry season in areas of seasonal malaria transmission. Targeting this parasite reservoir before the transmission season could be a good strategy for malaria control. We are conducting a randomized double blind placebo controlled mass drug administration trial in eight village to clear the dry season low level parasitaemia with an ultimate aim of controlling malaria in eastern Sudan.

Sex: All

Ages: 1+ year old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• All residents of the 8 villages

Exclusion criteria

• Pregnancy
• History of allergy to sulfa drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

0 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Description:

1:Active comparator sulfadoxine-pyrimethamine plus artesunate

Treatment:

Drug: Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)

2

Placebo Comparator group

Description:

2:placebo comparator

Treatment:

Drug: placebo tablet similar to active drug in shape and size